KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Liabilities and Shareholders Equity (2016 - 2025)

Gsk (GSK) has 3 years of Liabilities and Shareholders Equity data on record, last reported at $74.7 billion in Q4 2018.

  • For Q4 2018, Liabilities and Shareholders Equity changed 0.18% year-over-year to $74.7 billion; the TTM value through Dec 2021 reached $74.7 billion, down 50.05%, while the annual FY2018 figure was $77.6 billion, 6.77% up from the prior year.
  • Liabilities and Shareholders Equity reached $74.7 billion in Q4 2018 per GSK's latest filing, roughly flat from $74.9 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $74.9 billion in Q4 2017 and bottomed at $73.5 billion in Q4 2016.
  • Average Liabilities and Shareholders Equity over 3 years is $74.3 billion, with a median of $74.7 billion recorded in 2018.
  • Peak YoY movement for Liabilities and Shareholders Equity: grew 1.91% in 2017, then dropped 0.18% in 2018.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $73.5 billion in 2016, then grew by 1.91% to $74.9 billion in 2017, then dropped by 0.18% to $74.7 billion in 2018.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $74.7 billion in Q4 2018, $74.9 billion in Q4 2017, and $73.5 billion in Q4 2016.